cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13130/rd_unimi/awv4gb/usx8oe
title: Gennaio_1896_Pagina_112.jpg

description: Bulletin of 1896/01/28
DOI: 10.13130/rd_unimi/nsvbhr/jwhhmv
title: Giugno_1890_Pagina_035.jpg

description: Bulletin of 1890/06/09
DOI: 10.13130/rd_unimi/v8alup/nd9h2q
title: Giugno_1891_Pagina_032.jpg

description: Bulletin of 1891/06/08
DOI: 10.25934/pr00012187
title: A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

description: To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
DOI: 10.13130/rd_unimi/rjrjox/ve8c0a
title: Luglio_1895_Pagina_059.jpg

description: Bulletin of 1895/07/15
DOI: 10.13130/rd_unimi/xu1sm0/c0vfap
title: Giugno_1893_Pagina_010.jpg

description: Bulletin of 1893/06/03
DOI: 10.25934/pr00012188
title: An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

description: This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
DOI: 10.13130/rd_unimi/6np0bt/4tm5ri
title: Gennaio_1894_Pagina_118.jpg

description: Bulletin of 1894/01/30
DOI: 10.13130/rd_unimi/cbrkhv/jaiuzr
title: Gennaio_1927_Pagina_025.jpg

description: Bulletin of 1927/01/07
DOI: 10.25574/03134
title: Chandra X-ray Observatory ObsId 03134

description: SEARCH FOR AN INTERMEDIATE MASS BLACK HOLE IN THE STARBURST GALAXY NGC2146
DOI: 10.25934/pr00012189
title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

description: The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
DOI: 10.25934/pr00012190
title: A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

description: This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).
DOI: 10.13130/rd_unimi/awv4gb/haujm0
title: Gennaio_1896_Pagina_113.jpg

description: Bulletin of 1896/01/29
DOI: 10.13130/rd_unimi/gsbgp1/ylsvdv
title: Giugno_1889_Pagina_052.jpg

description: Bulletin of 1889/06/13
DOI: 10.13130/rd_unimi/nsvbhr/tnc1wc
title: Giugno_1890_Pagina_036.jpg

description: Bulletin of 1890/06/09
DOI: 10.15468/dl.d2hnr2
title: Occurrence Download

description: A dataset containing 119 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((-60.190048 -29.011428, -60.270333 -29.016958, -60.348667 -29.033413, -60.423143 -29.060393, -60.491947 -29.097241, -60.553394 -29.14306, -60.605978 -29.196733, -60.648399 -29.256949, -60.679602 -29.322235, -60.6988 -29.390992, -60.705498 -29.461532, -60.699505 -29.53212, -60.680943 -29.601017, -60.650244 -29.66652, -60.608147 -29.72701, -60.555675 -29.780987, -60.494116 -29.827109, -60.424989 -29.864232, -60.350008 -29.891429, -60.271038 -29.908023, -60.190048 -29.913601, -60.109058 -29.908023, -60.030088 -29.891429, -59.955107 -29.864232, -59.88598 -29.827109, -59.824421 -29.780987, -59.771949 -29.72701, -59.729852 -29.66652, -59.699153 -29.601017, -59.680591 -29.53212, -59.674598 -29.461532, -59.681296 -29.390992, -59.700494 -29.322235, -59.731697 -29.256949, -59.774118 -29.196733, -59.826702 -29.14306, -59.888149 -29.097241, -59.956953 -29.060393, -60.031429 -29.033413, -60.109763 -29.016958, -60.190048 -29.011428))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 119 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0054863-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00012191
title: A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

description: Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
DOI: 10.13130/rd_unimi/jvs9pt/hqa0fl
title: Giugno_1892_Pagina_011.jpg

description: Bulletin of 1892/06/03
DOI: 10.13130/rd_unimi/v8alup/tvlyt7
title: Giugno_1891_Pagina_033.jpg

description: Bulletin of 1891/06/09
DOI: 10.25934/pr00012192
title: A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma.

description: This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic RCC. Approximately 160 eligible patients will be stratified based on the ECOG performance status (0 vs. 1) and number of metastatic sites of disease (0 and 1 vs. \>=2). The study consists of two treatment periods of 10 weeks with a 2-week wash-out period between the two treatment periods. Patients will receive pazopanib and sunitinib treatment sequentially in a double-blinded fashion. The primary objective of the study is to assess how the tolerability and safety differences between pazopanib and sunitinib translate into patient preference, defined by the patient's stated preference for which drug they may prefer to continue treatment with at end of study. The secondary objectives are to evaluate the reason for patient preference as assessed by a patient preference questionnaire; to evaluate fatigue as assessed by FACIT-Fatigue and quality of life as assessed by EuroQoL EQ-5D; to evaluate dose modifications and time to dose modification; and to evaluate safety.
DOI: 10.13130/rd_unimi/cbrkhv/wrhkur
title: Gennaio_1927_Pagina_026.jpg

description: Bulletin of 1927/01/07
DOI: 10.13130/rd_unimi/rjrjox/bbkqei
title: Luglio_1895_Pagina_060.jpg

description: Bulletin of 1895/07/15
DOI: 10.13130/rd_unimi/xu1sm0/prgjdp
title: Giugno_1893_Pagina_011.jpg

description: Bulletin of 1893/06/03
DOI: 10.25574/03135
title: Chandra X-ray Observatory ObsId 03135

description: SEARCH FOR AN INTERMEDIATE MASS BLACK HOLE IN THE STARBURST GALAXY NGC2146
DOI: 10.25934/pr00012193
title: A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

description: BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma. Subjects will be randomized to receive 150 mg of GSK2118436 twice daily or 1000 mg/m2 DTIC every 3 weeks and continue on treatment until disease progression, death, or unacceptable adverse event. Subjects who progress on DTIC will be allowed to crossover to an optional extension arm of the study to receive GSK2118436.
DOI: 10.13130/rd_unimi/6np0bt/4ms1ag
title: Gennaio_1894_Pagina_119.jpg

description: Bulletin of 1894/01/30
DOI: 10.13130/rd_unimi/awv4gb/simfia
title: Gennaio_1896_Pagina_114.jpg

description: Bulletin of 1896/01/29
DOI: 10.13130/rd_unimi/gsbgp1/nxowjh
title: Giugno_1889_Pagina_053.jpg

description: Bulletin of 1889/06/14
DOI: 10.25934/pr00012194
title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

description: There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + placebo in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer refractory to NSAI.
DOI: 10.25934/pr00012195
title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload

description: This was a randomized, double-blind trial to evaluate deferasirox vs placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload .The trial was conducted in 17 countries, started in 2010 and ended in 2018.
DOI: 10.13130/rd_unimi/jvs9pt/x7y3lh
title: Giugno_1892_Pagina_012.jpg

description: Bulletin of 1892/06/03
DOI: 10.13130/rd_unimi/nsvbhr/mtxyos
title: Giugno_1890_Pagina_037.jpg

description: Bulletin of 1890/06/10
DOI: 10.25934/pr00012196
title: A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer

description: This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (NSAI) therapy in Novartis Oncology emergent growth market (EGM) countries.Data was presented by Asian countries vs Non-Asian countries to confirm no difference in safety and efficacy. Summary statistics were presented.
DOI: 10.13130/rd_unimi/rjrjox/hd5fiv
title: Luglio_1895_Pagina_049.jpg

description: Bulletin of 1895/07/13
DOI: 10.13130/rd_unimi/v8alup/wlnjft
title: Giugno_1891_Pagina_034.jpg

description: Bulletin of 1891/06/09
DOI: 10.13130/rd_unimi/xu1sm0/nbus3l
title: Giugno_1893_Pagina_012.jpg

description: Bulletin of 1893/06/03
DOI: 10.25574/03136
title: Chandra X-ray Observatory ObsId 03136

description: SEARCH FOR AN INTERMEDIATE MASS BLACK HOLE IN THE STARBURST GALAXY NGC2146
DOI: 10.25934/pr00012197
title: An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy

description: Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.
DOI: 10.13130/rd_unimi/cbrkhv/ra76jr
title: Gennaio_1927_Pagina_027.jpg

description: Bulletin of 1927/01/07
DOI: 10.25934/pr00012198
title: The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

description: Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.
DOI: 10.13130/rd_unimi/6np0bt/r4hm0u
title: Gennaio_1894_Pagina_120.jpg

description: Bulletin of 1894/01/30
DOI: 10.13130/rd_unimi/awv4gb/4spxlw
title: Gennaio_1896_Pagina_115.jpg

description: Bulletin of 1896/01/29
DOI: 10.13130/rd_unimi/gsbgp1/bx1mmq
title: Giugno_1889_Pagina_054.jpg

description: Bulletin of 1889/06/14
DOI: 10.25934/pr00012199
title: A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

description: This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The purpose was to compare the efficacy, safety and tolerability of Ruxolitinib (INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential thrombocythemia myelofibrosis (PET-MF).
DOI: 10.13130/rd_unimi/jvs9pt/pl2ntb
title: Giugno_1892_Pagina_013.jpg

description: Bulletin of 1892/06/04
DOI: 10.13130/rd_unimi/nsvbhr/bktrk2
title: Giugno_1890_Pagina_038.jpg

description: Bulletin of 1890/06/10
DOI: 10.25574/03137
title: Chandra X-ray Observatory ObsId 03137

description: SEARCHING FOR MISSING LINK BETWEEN ULTLALUMINOUS INFRARED GALAXIES AND OPTICALLY-SELECTED QUASARS
DOI: 10.25934/pr00012200
title: Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

description: This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase
DOI: 10.13130/rd_unimi/cbrkhv/hsc5lb
title: Gennaio_1927_Pagina_028.jpg

description: Bulletin of 1927/01/07
DOI: 10.13130/rd_unimi/rjrjox/b3qoqr
title: Luglio_1895_Pagina_062.jpg

description: Bulletin of 1895/07/16
DOI: 10.13130/rd_unimi/v8alup/dtg8c0
title: Giugno_1891_Pagina_035.jpg

description: Bulletin of 1891/06/09
DOI: 10.13130/rd_unimi/xu1sm0/3v4xnq
title: Giugno_1893_Pagina_013.jpg

description: Bulletin of 1893/06/04
DOI: 10.25934/pr00012201
title: ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

description: The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.
DOI: 10.13130/rd_unimi/awv4gb/pq97lk
title: Gennaio_1896_Pagina_116.jpg

description: Bulletin of 1896/01/29
DOI: 10.25934/pr00012202
title: A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

description: In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.
DOI: 10.13130/rd_unimi/6np0bt/n1emla
title: Gennaio_1894_Pagina_121.jpg

description: Bulletin of 1894/01/31
DOI: 10.13130/rd_unimi/gsbgp1/7zpgo1
title: Giugno_1889_Pagina_055.jpg

description: Bulletin of 1889/06/14
DOI: 10.13130/rd_unimi/nsvbhr/2i83hz
title: Giugno_1890_Pagina_039.jpg

description: Bulletin of 1890/06/10
DOI: 10.25574/03138
title: Chandra X-ray Observatory ObsId 03138

description: MASSIVE GAS INFLOW IN RADIO GALAXIES
DOI: 10.25934/pr00012203
title: A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies.

description: The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions:Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1)Group A - Imatinib failure only (arms 2, 3 and 4)* imatinib-resistant or intolerant CML - Chronic Phase (CP)* imatinib-resistant or intolerant CML - Accelerated Phase (AP)* imatinib-resistant or intolerant CML - Blast Crisis (BC)Group B - Imatinib and other TKI failure (arms 2, 3 and 4)* imatinib-resistant or intolerant CML - Chronic Phase (CP)* imatinib-resistant or intolerant CML - Accelerated Phase (AP)* imatinib-resistant or intolerant CML - Blast Crisis (BC)Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5)Systemic mastocytosis (Sm) (arm 6)
DOI: 10.5281/zenodo.17703052
title: ROR Data

description: Data dump from the Research Organization Registry (ROR), a community-led registry of open identifiers for research organizations.

Release v1.74 contains ROR IDs and metadata for 120,196 research organizations in JSON and CSV format, in schema versions 1 and 2. This includes the addition of 299 new records and metadata updates to 1,292 existing records. See the release notes.

Data format

Beginning with release v1.45 on 11 April 2024, data releases contain JSON and CSV files formatted according to both  schema v1 and schema v2. v2 files have `_schema_v2` appended to the end of the filename, ex v1.45-2024-04-11-ror-data_schema_v2.json. In order to maintain compatibility with previous releases, v1 files have no version information in the filename, ex v1.45-2024-04-11-ror-data.json

For both versions, the CSV file contains a subset of fields from the JSON file, some of which have been flattened for easier parsing. As ROR records and the ROR schema are maintained in JSON, CSVs are for convenience only. JSON is the format of record.

Release versioning

Beginning with v1.45 in April 2024, ROR has introduced schema versioning, with files available in schema v1 and schema v2. The ROR API default version is v2 as of July 2025, and v1 of the ROR API and dataset will be deprecated entirely in December 2025. At that time, the data dump major version will be incremented to 2 per below.

Data releases are versioned as follows:



Minor versions (ex 1.1, 1.2, 1.3):  Contain changes to data, such as a new records and updates to existing records. No changes to the data model/structure.

Patch versions (ex 1.0.1):  Used infrequently to correct errors in a release. No changes to the data model/structure.

Major versions (ex 1.x, 2.x, 3.x):  Contains changes to data model/structure, as well as the data itself. Major versions will be released with significant advance notice.


For convenience, the date is also included in the release file name, ex: v1.0-2022-03-15-ror-data.zip.

The ROR data dump is provided under the  Creative Commons CC0 Public Domain Dedication. Location data in ROR comes from GeoNames and is licensed under a Creative Commons Attribution 4.0 license.
DOI: 10.13130/rd_unimi/jvs9pt/h6175g
title: Giugno_1892_Pagina_014.jpg

description: Bulletin of 1892/06/04
DOI: 10.13130/rd_unimi/xu1sm0/pylgz0
title: Giugno_1893_Pagina_014.jpg

description: Bulletin of 1893/06/04
DOI: 10.25934/pr00012204
title: A Study to Determine the Safety and Efficacy of STI571 in Patients With Chronic Myeloid Leukemia Who Are Hematologically or Cytogenetically Resistant or Refractory to Interferon-Alpha, or Intolerant of, Interferon-Alpha

description: RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia.PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myeloid leukemia that has not responded to interferon alfa.
DOI: 10.13130/rd_unimi/awv4gb/tpfzvf
title: Gennaio_1896_Pagina_117.jpg

description: Bulletin of 1896/01/30
DOI: 10.13130/rd_unimi/cbrkhv/nh1btp
title: Gennaio_1927_Pagina_029.jpg

description: Bulletin of 1927/01/08
DOI: 10.13130/rd_unimi/rjrjox/qitumx
title: Luglio_1895_Pagina_051.jpg

description: Bulletin of 1895/07/13
DOI: 10.13130/rd_unimi/v8alup/fsxe8n
title: Giugno_1891_Pagina_036.jpg

description: Bulletin of 1891/06/09
DOI: 10.25934/pr00012205
title: A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy

description: This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. Patients will be randomized into either drug treatment or placebo group at 1:1 ratio, and receive their respective treatment for 8 weeks. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.
DOI: 10.13130/rd_unimi/6np0bt/43axtd
title: Gennaio_1894_Pagina_122.jpg

description: Bulletin of 1894/01/31
DOI: 10.13130/rd_unimi/gsbgp1/uycj8r
title: Giugno_1889_Pagina_056.jpg

description: Bulletin of 1889/06/14
DOI: 10.25574/03139
title: Chandra X-ray Observatory ObsId 03139

description: PROBING THE X-RAY EMISSION OF HIGH LUMINOSITY EMISSION LINE GALAXIES: QUASAR-2s AND THE STARBURST-AGN CONNECTION
DOI: 10.25934/pr00012206
title: A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients

description: The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.
DOI: 10.25934/pr00012207
title: A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion

description: The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients
DOI: 10.13130/rd_unimi/jvs9pt/gzk2x0
title: Giugno_1892_Pagina_015.jpg

description: Bulletin of 1892/06/04
DOI: 10.13130/rd_unimi/nsvbhr/yxhmlj
title: Giugno_1890_Pagina_040.jpg

description: Bulletin of 1890/06/10